# Clinical Core

> **NIH NIH U19** · MAYO CLINIC ROCHESTER · 2021 · $7,627,451

## Abstract

ABSTRACT – ARTFL LEFFTDS Longitudinal FTLD: CLINICAL CORE
The ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) protocol represents an
expanded and integrated international research consortium involving seven cores and two projects; ALLFTD is
designed to substantially and comprehensively increase the amount of longitudinal data, numbers of
biospecimen samples and MRI scans that are publicly available for research in FTLD, to ultimately foster
development of disease-modifying therapies. Previously, the Advancement of Research and Treatment in
Frontotemporal Lobar Degeneration (ARTFL; U54 NS092089) and Longitudinal Evaluation of Familial
Frontotemporal Dementia Subjects (LEFFTDS; U01 AG045390) protocols collectively enrolled >1100
participants at 18 sites, including >380 members of families affected by MAPT, GRN and C9orf72 mutations
(surpassing the original LEFFTDS target of 300), with the remaining participants being sporadic FTLD patients
enrolled through ARTFL. Detailed clinical and neuropsychological data, including (but not limited to) the
National Alzheimer's Coordinating Center (NACC) Uniform Data Set Version 3 and FTLD Module has been
completed, with almost 1200 data packets uploaded to NACC to date. Biofluid samples, including DNA, PBMC,
mRNA, plasma and serum on the vast majority of participants, and CSF on a subset, have been collected
during the ARTFL/LEFFTDS studies, transferred and processed at the National Centralized Repository for
Alzheimer's Disease and Related Dementias. Over 900 MRI scans using a standardized protocol have been
performed in 585 participants, and these data have undergone quality control inspection and transferal to the
Laboratory of NeuroImaging. All data, samples and scans are available and have been used by investigators
within and outside of the ARTFL/LEFFTDS Consortium. The ALLFTD Clinical Core will continue to build on the
obvious success of the ARTFL and LEFFTDS protocols by recruiting additional participants in either the
longitudinal or biofluid-focused arm. The Clinical Core will enroll and evaluate up to 1100 participants annually
in the longitudinal arm, and will include 500 asymptomatic and mildly symptomatic members of kindreds with
familial FTLD and 600 mildly symptomatic sporadic FTLD patients. Approximately 1000 additional FTLD
patients will be recruited into the biofluid focused arm. In partnership with the FTD Disorders Registry,
participants in both arms will be followed remotely, requested to complete questionnaires and provided with
periodic updates and information of FTLD research opportunities. The sites in the Clinical Core will provide
high quality clinical data, biofluid samples and MRI scans to be integrated for use in all cores and projects, and
shared with the scientific community.

## Key facts

- **NIH application ID:** 10208702
- **Project number:** 5U19AG063911-03
- **Recipient organization:** MAYO CLINIC ROCHESTER
- **Principal Investigator:** Bradley F Boeve
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $7,627,451
- **Award type:** 5
- **Project period:** 2019-09-15 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10208702

## Citation

> US National Institutes of Health, RePORTER application 10208702, Clinical Core (5U19AG063911-03). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10208702. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*